Literature DB >> 24316907

Hodgkin lymphoma: pathology, pathogenesis, and a plethora of potential prognostic predictors.

Rebecca L King1, Matthew T Howard, Adam Bagg.   

Abstract

Hodgkin lymphoma (HL) encompasses 2 unique clinicopathologic entities, classical Hodgkin lymphoma (CHL) (∼95% of cases) and nodular lymphocyte predominant HL (∼5% of cases). Both subtypes demonstrate a paucity of surreptitious (in CHL) neoplastic B cells within a background of reactive inflammatory cells underscoring both the relatedness of these 2 entities to each other, as well as their distinction from other types of lymphoid neoplasia. Clinically, they are primarily nodal diseases that disseminate in a predictable manner to contiguous nodal regions. The biology of HL as a whole, as well as the genetic and pathologic features that distinguish CHL from nodular lymphocyte predominant HL and other lymphomas has been the subject of a wealth of investigation in recent decades. The aim of this review is to detail the pathologic features of HL and to highlight the recent insights into its molecular basis and the myriad prognostic markers being described.

Entities:  

Mesh:

Year:  2014        PMID: 24316907     DOI: 10.1097/PAP.0000000000000002

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  3 in total

Review 1.  The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?

Authors:  Magdalena Witkowska; Agata Majchrzak; Piotr Smolewski
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

Review 2.  Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.

Authors:  Magdalena Witkowska; Piotr Smolewski
Journal:  J Immunol Res       Date:  2018-04-11       Impact factor: 4.818

Review 3.  The Grey Zones of Classic Hodgkin Lymphoma.

Authors:  Jan Bosch-Schips; Massimo Granai; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.